NCT03836352: A reported trial by ImmunoVaccine Technologies, Inc. (IMV Inc.)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03836352 |
|---|---|
| Title | A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours. |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 21, 2018 |
| Completion date | Dec. 31, 2023 |
| Required reporting date | Dec. 30, 2024, midnight |
| Actual reporting date | Sept. 11, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |